Ligand Pharmaceuticals Reiterates FY25 Outlook - Update
Ligand Pharmaceuticals, Inc. (LGND) has reiterated its adjusted earnings and revenue guidance for fiscal 2025 while reporting its first-quarter financial results. The company projects adjusted earnings between $6.00 and $6.25 per share, with revenues expected to range from $180 million to $200 million. Analysts anticipate earnings of $6.11 per share and revenues of $191.30 million for the year, excluding special items.
While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and revenue guidance for fiscal 2025.
For fiscal 2025, the company continues to project adjusted earnings in the range of $6.00 to $6.25 per share on revenues between $180 million to $200 million.
On average, analysts polled expect the company to report earnings of $6.11 per share on revenues of $191.30 million for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
